3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
7
Neoplasms
3
Neoplasm Metastasis
2
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Liposarcoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Gliosarcoma
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
Doxorubicin
5
pazopanib
4
Ifosfamide
3
pembrolizumab
2
Sunitinib
2
Radiotherapy, Conformal
2
Radiotherapy
2
tremelimumab
1
temsirolimus
1
sintilimab
1
saracatinib
1
sapanisertib
1
romidepsin
1
olaratumab
1
liposomal doxorubicin
1
indolepropanol phosphate
1
eribulin
1
durvalumab
1
Watchful Waiting
1
Surgical Procedures, Operative
1
Sorafenib
1
Razoxane
1
Radiotherapy, Intensity-Modulated
1
Radiation
1
Polymerase Chain Reaction
1
Observation
1
Nivolumab
1
Neoadjuvant Therapy
1
Methotrexate
1
MLN 8237
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Histiocytoma, Malignant Fibrous
×
olaratumab
×
Clear all
NCT02451943
2025-07-15
ANNOUNCE
Eli Lilly and Company
Phase 3
Completed
509 enrolled
23 charts